Nestor Ciociano1, Lucia Bagnasco. 1. Scuola di Specializzazione Farmacia Ospedaliera, Università degli Studi di Salerno, Via Tenente Nastri 160, 84084, Fisciano, Salerno, Italy, nestorciociano@hotmail.com.
Abstract
BACKGROUND: The implementation of preventive measures of look-alike/sound-alike drugs incidents has given rise to a fundamental rule in Clinical Risk Management, but the problem is underestimated, endorsed by the absence or inadequate presence of specific uniformed procedures. In literature, there are few reviews about look-alike/sound-alike drugs. AIM OF THE REVIEW: To collect and summarize best practice and significant technological solutions proposed by different disciplines involved in look-alike/soundalike drugs limiting solution research. METHOD: A PubMed (any date) and EMBASE (all years) search was conducted in January 2013 with look alike sound alike drug [look AND (sound/exp OR sound) AND alike AND (drug/exp OR drug)] as search term. Later, references were selected focusing on lookalike/sound-alike drugs original research describing incident, identifying health operator difficulty, testing any type of intervention against errors, reporting a qualitative or quantitative description of the look-alike/sound-alike drugs errors. RESULTS: Forty and ninety-four articles were identified by a PubMed and Embase search respectively, with search term and limits described above. Later, articles not respecting selection criteria or overlapping were eliminated. In the end, 14 references were considered, 10 being from PubMed and 4 from Embase. CONCLUSION: Results show and confirm the multidisciplinary interest of the research on look-alike/sound-alike drugs, and the difficulty to perform systematic review or metaanalysis for many clinical questions that have great relevance. This review has identified technology and management solutions that could effectively limit, or eliminate, look-alike/sound-alike drugs errors in hospital wards, or outside the hospital where the risk is more uncontrollable: however look-alike/sound-alike drugs therapy errors are not supported by reliable statistics but events reported in the literature can not be underestimated.
BACKGROUND: The implementation of preventive measures of look-alike/sound-alike drugs incidents has given rise to a fundamental rule in Clinical Risk Management, but the problem is underestimated, endorsed by the absence or inadequate presence of specific uniformed procedures. In literature, there are few reviews about look-alike/sound-alike drugs. AIM OF THE REVIEW: To collect and summarize best practice and significant technological solutions proposed by different disciplines involved in look-alike/soundalike drugs limiting solution research. METHOD: A PubMed (any date) and EMBASE (all years) search was conducted in January 2013 with look alike sound alike drug [look AND (sound/exp OR sound) AND alike AND (drug/exp OR drug)] as search term. Later, references were selected focusing on lookalike/sound-alike drugs original research describing incident, identifying health operator difficulty, testing any type of intervention against errors, reporting a qualitative or quantitative description of the look-alike/sound-alike drugs errors. RESULTS: Forty and ninety-four articles were identified by a PubMed and Embase search respectively, with search term and limits described above. Later, articles not respecting selection criteria or overlapping were eliminated. In the end, 14 references were considered, 10 being from PubMed and 4 from Embase. CONCLUSION: Results show and confirm the multidisciplinary interest of the research on look-alike/sound-alike drugs, and the difficulty to perform systematic review or metaanalysis for many clinical questions that have great relevance. This review has identified technology and management solutions that could effectively limit, or eliminate, look-alike/sound-alike drugs errors in hospital wards, or outside the hospital where the risk is more uncontrollable: however look-alike/sound-alike drugs therapy errors are not supported by reliable statistics but events reported in the literature can not be underestimated.
Authors: Zizi Campmans; Arianne van Rhijn; René M Dull; Jacqueline Santen-Reestman; Katja Taxis; Sander D Borgsteede Journal: PLoS One Date: 2018-05-29 Impact factor: 3.240
Authors: Viktoria S Wurmbach; Steffen J Schmidt; Anette Lampert; Eduard Frick; Michael Metzner; Simone Bernard; Petra A Thürmann; Stefan Wilm; Achim Mortsiefer; Attila Altiner; Lisa Sparenberg; Joachim Szecsenyi; Frank Peters-Klimm; Petra Kaufmann-Kolle; Walter E Haefeli; Hanna M Seidling Journal: BMC Med Inform Decis Mak Date: 2020-07-08 Impact factor: 2.796
Authors: Pamela M Garabedian; Adam Wright; Isabella Newbury; Lynn A Volk; Alejandra Salazar; Mary G Amato; Aaron W Nathan; Katherine J Forsythe; William L Galanter; Kevin Kron; Sara Myers; Joanna Abraham; Sarah K McCord; Tewodros Eguale; David W Bates; Gordon D Schiff Journal: JAMA Netw Open Date: 2019-03-01
Authors: Irene Lizano-Díez; Carlos Figueiredo-Escribá; M Ángeles Piñero-López; Cecilia F Lastra; Eduardo L Mariño; Pilar Modamio Journal: BMC Health Serv Res Date: 2020-01-29 Impact factor: 2.655
Authors: Steffen J Schmidt; Viktoria S Wurmbach; Anette Lampert; Simone Bernard; Walter E Haefeli; Hanna M Seidling; Petra A Thürmann Journal: Eur J Clin Pharmacol Date: 2020-04-01 Impact factor: 2.953